We Have Known About Ibogaine for Decades. So Why Are We Here?
There is something difficult to sit with when looking at the history of ibogaine.
Its potential in treating opioid dependence has not just recently emerged. It has been known, observed, and discussed for decades. And yet, despite this, ibogaine remains largely outside of the United States medical system, while opioid use disorder continues to impact millions of individuals, families, and communities.
This raises a question that is not only medical, but systemic.
How did we arrive here?
The Role of NIDA
The National Institute on Drug Abuse was aware of ibogaine’s potential long before the current wave of psychedelic research began to gain traction.
There was a period in which ibogaine entered the field of serious consideration, not as a fringe compound, but as something that warranted deeper investigation in the context of addiction treatment. Early reports and observational data suggested that ibogaine may interrupt withdrawal symptoms and disrupt compulsive patterns of opioid use in ways that were not being seen with conventional approaches.
However, this path did not fully develop. Research slowed, funding did not expand, and momentum shifted elsewhere. This was not because the questions had been fully answered, but because the risks, the unknowns, and the limitations of the existing medical and regulatory frameworks made it difficult to proceed.
A Timeline We Rarely Sit With
To understand the present, it is important to look clearly at the sequence of events that followed.
In the late 1960s and early 1970s, ibogaine began to surface in conversations around addiction interruption. Around the same time, in 1970, the Controlled Substances Act was enacted, classifying ibogaine as a Schedule I substance. This classification significantly limited the ability to study it within the United States.
Through the 1970s and 1980s, interest in ibogaine did not disappear, but it did not receive the institutional support required for large-scale development. In the 1990s, there was a brief resurgence of attention, with efforts made to move ibogaine toward clinical trials. These efforts ultimately did not result in sustained advancement.
Meanwhile, opioid use continued to evolve.
Heroin use increased across multiple waves. Overdose rates climbed. Entire communities began to feel the cumulative effects of addiction. In the mid-1990s, prescription opioids, including OxyContin, entered widespread medical use. Addiction expanded rapidly, often beginning within the healthcare system itself.
From the early 2000s to the present, the opioid epidemic escalated into one of the most significant public health crises in modern history. Treatment systems expanded, largely centering around methadone and buprenorphine, with a focus on stabilization and harm reduction.
At the same time, ibogaine did not disappear. It continued to be used in other countries and in unregulated settings, often without the level of medical oversight that could have made its use safer and more consistent.
What We Built Instead
In the absence of deeper exploration into alternatives like ibogaine, the system organized around what it could support.
Methadone and buprenorphine became central to the treatment of opioid use disorder. These medications have helped many individuals reduce harm, stabilize their lives, and avoid overdose. Their role is significant and should not be minimized.
At the same time, they were developed within a model that prioritizes stabilization, risk reduction, and long-term management. They are highly effective within that framework.
But stabilization is not the same as resolution.
These approaches often support survival, but they do not always facilitate the kind of interruption, reorganization, and transformation that some individuals are seeking in their recovery process.
A Systems Question, Not Just a Medical One
It is easy to frame this as a question about a single compound.
Why wasn’t ibogaine developed?
But the more honest question may be broader.
What kind of system determines what is allowed to develop?
Ibogaine presents real challenges. It carries medical risk, particularly related to cardiac function. It requires careful screening, medical oversight, and an infrastructure capable of managing high-intensity, extended experiences. It does not fit easily into brief appointments or standardized treatment protocols.
At the same time, medical decision-making does not occur in a vacuum.
In a system where financial incentives, scalability, and liability influence what is prioritized, the treatments that move forward are often those that can be more easily standardized, regulated, and integrated into existing structures.
The history of Purdue Pharma and the widespread distribution of OxyContin made this visible in a way that is difficult to ignore. A medication was introduced, its risks were minimized, and it contributed to a crisis that continues to unfold.
Within that context, the question of why more complex, less scalable treatments were not pursued with the same intensity becomes more than a scientific inquiry.
It becomes a systemic one.
What Was Lost in the Gap
While research slowed, addiction did not.
While development stalled, suffering expanded.
And while regulated systems struggled to engage with compounds like ibogaine, individuals continued to seek out alternatives, often in environments that lacked the safeguards of a medical framework.
This is not simply a story about a molecule.
It is a story about timing, about the structure of systems, and about the consequences of what is prioritized, funded, and developed, and what is not.
Where This Leaves Us
Ibogaine is now re-entering the conversation.
Not as something new, but as something that was seen, set aside, and is now being revisited in a very different context. Research interest is growing. Public awareness is increasing. Questions that were once peripheral are becoming more central.
The question is no longer just whether ibogaine has potential.
It is whether we are prepared to engage with it differently this time, with the level of care, structure, and responsibility required to support both its risks and its possibilities.
Closing
Imagine a different timeline.
One in which ibogaine was not pushed to the margins, but carefully studied and developed within medical systems capable of holding its complexity.
One in which treatment for opioid use disorder was not limited to stabilization alone, but included the possibility of deeper interruption and reorganization.
One in which OxyContin did not enter a system already strained by unresolved addiction.
How many lives would have been different?
How many would have been saved?
What would our system look like today if we had built it to support transformation, rather than only managing survival?
Add comment
Comments